American Journal of Cardiology
Volume 101, Issue 12 , Pages 1689-1693 , 15 June 2008

Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction

  • Zongliang Lu, MD, PhD

      Affiliations

    • Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, Peoples Republic of China
    • ,
  • Wenrong Kou, MD

      Affiliations

    • Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, Peoples Republic of China
    • ,
  • Baomin Du, MD

      Affiliations

    • WBL Peking University Biotech Co. Ltd, Beijing, Peoples Republic of China
    • ,
  • Yangfeng Wu, MD

      Affiliations

    • Peking University Health Science Center, Peoples Republic of China
    • ,
  • Shuiping Zhao, MD, PhD

      Affiliations

    • The Second Xianya Hospital of Central South University, Peoples Republic of China
    • ,
  • Osvaldo A. Brusco, MD

      Affiliations

    • Texas A&M School of Medicine, Corpus Christi, Texas
    • ,
  • John M. Morgan, MD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.
    • ,
  • David M. Capuzzi, MD, PhD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.
    • Corresponding Author InformationCorresponding author: Tel: 610-645-8426; Fax: 610-645-2205.
    • ,
  • Chinese Coronary Secondary Prevention Study Group

Received 8 June 2007 ,Revised 18 February 2008 ,Accepted 18 February 2008.

References 

  1. Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, et al. Multiple clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr Ther Res. 1997;58:964–978
  2. Liu L, Zhao S, Chend Y, Li Y. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem. 2003;49:1347–1352
  3. Zhao S, Liu L, Cheng Y, Li Y. Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis. 2003;168:375–380
  4. Zhao S, Liu L, Cheng Y, Shishehbor M, Hui M, Peng D, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004;110:915–920
  5. Li J, Hu S, Fang C, Hui R, Niao L, Yang Y, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta. 2005;352:217–224
  6. Lin C, Li T, Lai M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153:679–686
  7. Mak K, Ching C, Mukundan N, Sim S, Gao H, Wong H, et al. A randomization, parallel, double-blind study comparing the lipid lowering effect of Xuezhikang (Lipascor) with simvastatin in asymptomatic patients with hyperlipidaemia. ASEAN Heart J. 2005;13:15–20
  8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering on 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individual: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  11. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  12. Athyros VG, Papageorgiou AA, Mercouris BR. The Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Curr Med Res Opin. 2002;18:220–228
  13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158
  14. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231–236

 Members of the Chinese Coronary Secondary Prevention Study Group are listed in the Appendix.

 This study was supported by the Chinese National Scientific and Technological Projects, Peoples Republic of China, and sponsored by WPL Peking University Biotech Co. Ltd (WPU), Beijing, Peoples Republic of China.

PII: S0002-9149(08)00353-6

doi: 10.1016/j.amjcard.2008.02.056

American Journal of Cardiology
Volume 101, Issue 12 , Pages 1689-1693 , 15 June 2008

Article Tools

* Image Usage & Resolution